{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:00:31Z","timestamp":1792044031693,"version":"4.4.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,20]],"date-time":"2013-11-20T00:00:00Z","timestamp":1384905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.vaccine.2013.11.049","type":"journal-article","created":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T23:31:38Z","timestamp":1385508698000},"page":"733-739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths"],"prefix":"10.1016","volume":"32","author":[{"given":"Georges","family":"Van Kriekinge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Castellsagu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cibula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Demarteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.11.049_bib0005","series-title":"GLOBOCAN 2008 v2.0. Cancer incidence and mortality worldwide in 2008","author":"Ferlay","year":"2010"},{"key":"10.1016\/j.vaccine.2013.11.049_bib0010","series-title":"Data Query tool","author":"ICO. ICO (Institut Catal\u00e0 d\u2019Oncologia) Information Centre on HPV and Cancer (HPV Information Centre)","year":"2013"},{"issue":"1","key":"10.1016\/j.vaccine.2013.11.049_bib0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.vaccine.2013.11.049_bib0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","article-title":"Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis","volume":"88","author":"Clifford","year":"2003","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.vaccine.2013.11.049_bib0025","first-page":"1551","article-title":"Burden of disease associated with cervical cancer in Malaysia and potential costs and consequences of HPV vaccination","volume":"11","author":"Aljunid","year":"2010","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.vaccine.2013.11.049_bib0030","series-title":"Updated consensus guidelines for managing abnormal cervical cancer screening tests and cancer precursors","year":"2012"},{"issue":"9580","key":"10.1016\/j.vaccine.2013.11.049_bib0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"issue":"9686","key":"10.1016\/j.vaccine.2013.11.049_bib0040","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.11.049_bib0045","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"1","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2013.11.049_bib0050","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","article-title":"Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"1","author":"Wheeler","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2013.11.049_bib0055","series-title":"Introduction of HPV vaccines in European Union countries\u2013an update","year":"2012"},{"issue":"20","key":"10.1016\/j.vaccine.2013.11.049_bib0060","first-page":"626","article-title":"FDA licensure of bivalent human papillomavirus vaccine (HPV2 Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee of Immunization Practices (ACIP)","volume":"59","year":"2010","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2013.11.049_bib0065","series-title":"PPP conversion factor, GDP (LCU per international $)","author":"World Bank","year":"2012"},{"issue":"40","key":"10.1016\/j.vaccine.2013.11.049_bib0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vaccine.2009.06.097","article-title":"Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries","volume":"27","author":"Colantonio","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.11.049_bib0075","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/1471-2458-9-401","article-title":"A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females","volume":"9","author":"Anonychuk","year":"2009","journal-title":"BMC Public Health"},{"issue":"2","key":"10.1016\/j.vaccine.2013.11.049_bib0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10389-008-0228-3","article-title":"Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany","volume":"17","author":"Hillemanns","year":"2009","journal-title":"J of Public Health"},{"issue":"2","key":"10.1016\/j.vaccine.2013.11.049_bib0085","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/eurpub\/cki163","article-title":"The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany","author":"Siebert","year":"2006","journal-title":"Eur J Public Health"},{"issue":"7","key":"10.1016\/j.vaccine.2013.11.049_bib0090","doi-asserted-by":"crossref","first-page":"A445","DOI":"10.1016\/j.jval.2011.08.1163","article-title":"Costs and consequences of HPV vaccination in Thailand: results of a prevalence based model. (Abstract PCN62 presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress, 5\u20138 Nov, Madrid, Spain)","volume":"14","author":"Van Enckevort","year":"2011","journal-title":"Value Health"},{"issue":"44","key":"10.1016\/j.vaccine.2013.11.049_bib0095","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.vaccine.2009.08.004","article-title":"The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa","volume":"27","author":"Sinanovic","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.11.049_bib0100","series-title":"Consumer price index (2005=100)","author":"World Bank","year":"2012"},{"issue":"3","key":"10.1016\/j.vaccine.2013.11.049_bib0105","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ygyno.2011.01.029","article-title":"Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles","volume":"121","author":"Capri","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.vaccine.2013.11.049_bib0110","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ajog.2004.01.042","article-title":"The health care costs of cervical human papillomavirus \u2013 related disease","volume":"191","author":"Insinga","year":"2004","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.vaccine.2013.11.049_bib0115","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3111\/13696990801961611","article-title":"Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium","volume":"11","author":"Annemans","year":"2008","journal-title":"J Med Econ"},{"key":"10.1016\/j.vaccine.2013.11.049_bib0120","doi-asserted-by":"crossref","first-page":"a1284","DOI":"10.1136\/bmj.a1284","article-title":"Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis","volume":"337","author":"Arbyn","year":"2008","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.vaccine.2013.11.049_bib0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1471-0528.2011.02944.x","article-title":"The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis","volume":"118","author":"Bruinsma","year":"2011","journal-title":"BJOG"},{"key":"10.1016\/j.vaccine.2013.11.049_bib0130","article-title":"Safety and immunogenicity of human papillomavirus-16\/18 AS04-adjuvanted vaccine: a randomized trial in 10\u201325-year-old HIV-Seronegative African girls and young women","author":"Sow","year":"2012","journal-title":"J Infect Dis"},{"issue":"9783","key":"10.1016\/j.vaccine.2013.11.049_bib0135","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study","volume":"377","author":"Brotherton","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2013.11.049_bib0140","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.vaccine.2012.09.037","article-title":"Immune responses elicited by a fourth dose of the HPV-16\/18 AS04-adjuvanted vaccine in previously vaccinated adult women","volume":"31","author":"Moscicki","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2013.11.049_bib0145","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.vaccine.2012.10.067","article-title":"Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix((R))","volume":"31","author":"Kemp","year":"2012","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13015831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13015831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T00:31:40Z","timestamp":1564878700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13015831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0264410X13015831"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.11.049","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718195125.793532230","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.11.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}